dabogratinib — Interim data
2H 2026
The Company remains on track to report interim results from the safety sentinel cohort in 2H 2026.Source filing
TYRA biotech catalysts & pipeline
TYRA BIOSCIENCES INC · Data as of 2026-09-08
Upcoming catalysts
oral dabogratinib — Topline data
Sep 2026
The Company will host a conference call and webcast in September 2026 to report initial results from the SURF302 study, including safety results from more than 40 patients and efficacy from more than 20 patients in the aggregate at both QD dose levels.Source filing
dabogratinib — Initial data
2027
First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 -Source filing
oral dabogratinib — Topline data
Q1 2027
Initial results from the safety sentinel cohort, including 6-month annualized height velocity and safety data for dose levels 1-5, which will include an aggregate of approximately 25 children, are expected to be reported at the end of Q1 2027.Source filing
oral dabogratinib — Topline data
2027
Initial results from this study are expected in 2027.Source filing